# Clinical potential and challenges of spatially profiling tumor-infiltrating lymphocytes in early-stage breast cancer

## TL;DR

This paper explores how mapping immune cell interactions in breast cancer tumors could help predict patient outcomes, but more validation is needed before it can be used in clinics.

## Contribution

The paper highlights the potential of spatial profiling as a novel predictive biomarker for early-stage breast cancer.

## Key findings

- Spatial profiling using multispectral immunofluorescence shows promise as a predictive biomarker.
- Prospective validation is required for clinical adoption of this technique.
- Harmonization with existing biomarkers is necessary for integration into clinical practice.

## Abstract

Digitally automated spatial profiling of immune-tumor cell interactions using multispectral immunofluorescence holds promise as a biomarker to predict outcomes in early-stage breast cancer, but prospective validation and harmonization with existing biomarkers is necessary before clinical adoption.

In this Perspective, David Page and colleagues discuss how spatially profiling immune-tumor cell interactions using multispectral immunofluorescence analyses holds promise as a biomarker to predict outcomes in early-stage breast cancer.